Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants

• Published in: Hepatology (Baltimore, Md.) Vol. 70; no. 3; pp. 771 - 787
• Main Authors: Jensen, Sanne Brun, Fahnøe, Ulrik, Pham, Long V., Serre, Stéphanie Brigitte Nelly, Tang, Qi, Ghanem, Lubna, Pedersen, Martin Schou, Ramirez, Santseharay, Humes, Daryl, Pihl, Anne Finne, Filskov, Jonathan, Sølund, Christina Søhoel, Dietz, Julia, Fourati, Slim, Pawlotsky, Jean‐Michel, Sarrazin, Christoph, Weis, Nina, Schønning, Kristian, Krarup, Henrik, Bukh, Jens, Gottwein, Judith Margarete
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.09.2019; John Wiley and Sons Inc
• Subjects: Anilides - therapeutic use; Antiviral Agents - therapeutic use; Benzimidazoles - therapeutic use; Carbamates - therapeutic use; Cell culture; Chronic infection; Denmark; Disease hot spots; Disease resistance; Drug Resistance, Viral - genetics; Drug Therapy, Combination; Female; Genomes; Genotype; Genotype & phenotype; Genotypes; Haplotypes; Hepacivirus - drug effects; Hepacivirus - genetics; Hepatitis; Hepatitis C; Hepatitis C, Chronic - diagnosis; Hepatitis C, Chronic - drug therapy; Hepatology; Humans; Interferon; Male; Original; Prognosis; Protease Inhibitors - pharmacology; Protease Inhibitors - therapeutic use; Proteinase inhibitors; Quinoxalines - therapeutic use; Reproductive fitness; Sulfonamides - therapeutic use; Uracil - analogs & derivatives; Uracil - therapeutic use; Denmark

Protease inhibitors (PIs) are important components of treatment regimens for patients with chronic hepatitis C virus (HCV) infection. However, emergence and persistence of antiviral resistance could reduce their efficacy. Thus, defining resistance determinants is highly relevant for efforts to contr...